S115 Mechanisms to reverse impaired macrophage efferocytosis in copd

COPD patients have defective innate immunity, characterised in part by macrophage dysfunction. In established disease, both monocyte derived macrophages (MDM) and alveolar macrophages (AM), have impaired phagocytosis of bacteria and apoptotic cells (efferocytosis). Failure to adequately efferocytose dying cells leads to further release of inflammatory mediators and ongoing recruitment of immune cells, culminating in inflammation that is both damaging and ineffective. The transcription factor, Nrf2 is the master regulator of the antioxidant-response-element. Previous work using the non specific Nrf2 agonist, Sulforaphane, has partially restored defective bacterial phagocytosis in COPD AMs, however the specificity and mechanism of action in this context remains unknown. The role of Nrf2 activation in restoring macrophage efferocytosis in COPD has yet to be examined. We questioned if impaired macrophage phagocytosis and efferocytosis in COPD share a common mechanism and consequently if the defect in macrophage efferocytosis can be therapeutically manipulated using highly selective Nrf2 agonists. AMs and MDMs were isolated from patients with established COPD (GOLD stage 1–3). Macrophage efferocytosis of apoptotic neutrophils from each donor was correlated with bacterial internalisation of Streptococcus pneumoniae. Efferocytosis assays were carried out in the presence or absence of Sulforaphane and Compound 7, a highly specific Nrf2 agonist (supplied by GSK). Both COPD MDMs and AMs have significantly impaired phagocytosis of bacteria and apoptotic cells compared to Healthy Controls (p values all